Novartis Ag

Morphosys Ag

Adivo Gmbh

Markus Waldhuber

Josef Prassler

Thomas Tiller

Kathrin Ladetzki-Baehs

Ralf Strohner

Alexander W Koch

Maximilian Aigner

Matthew T Burger

Dominik Feuerbach

Christian Kunz

Tony Fleming

Vivek Rauniyar

Eveline Schaadt

Fabrizio Gasparini

Nathalie George

Rainer Wilcken

Joseph Anthony D'Alessio

Derya Shimshek

Verena Brand

Honnappa Srinivas

Eusebio Manchado Robles

The present invention provides synthetic canine antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries.

Canine antibody libraries

The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI ('Factor XIa'), and pharmaceutical compositions and methods of treatment comprising the same.

Factor XI antibodies and methods of use

This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Antibodies to PMEL17 and conjugates thereof

The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

TREM2 stabilizing antibodies

Growing community of inventors

Munich, Germany

Markus Waldhuber